Login
EN
[EN] English [FR] Français

Give us feedback
Explore
Search Special collections
Statistics
News
Help
Start on ORBi Deposit Profile Publication List Add your ORCID Tutorials Legal Information Training sessions
About
What's ORBi ?Impact and visibility Around ORBi About statistics About metrics OAI-PMH ORBi team Release Notes

Back

Home
Statistics

Statistics of First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Global Last 12 months Last 30 days

University of Liège
Place du 20-Août, 7
B- 4000 Liège
+32 4 366 21 11

ULiège Library

What's Open Access ?Open Access @ ULiège Publish in Open Access

ORBi (issn 2736-772X)

Referencing Project Background ORBi 10 years Around ORBi

Quick links

ULiège Mandate Tutorials ORCID OAI-PMH Output

Terms of use -Privacy Policy - ORBi is a project developed by University of Liege